Infantile hemangiomas with unusually prolonged growth phase: A case series

Archives of Dermatology

Volumn 144, Issue 12, 2008, Pages 1632-1637

  Brandling Bennett, Heather A ^a   Metry, Denise W ^b   Baselga, Eulalia ^c   Lucky, Anne W ^d   Adams, Denise M ^d   Cordisco, Maria R ^e   Frieden, Ilona J ^f  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^e HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; CORTICOSTEROID; VINCRISTINE SULFATE;

ARTICLE; ARTIFICIAL EMBOLISM; CARDIOMYOPATHY; CATHETER INFECTION; CLINICAL ARTICLE; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; CUSHINGOID SYNDROME; CYTOREDUCTIVE SURGERY; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG INTERMITTENT THERAPY; FEMALE; GROWTH RATE; HEMANGIOMA; HUMAN; INFANT; INFANTILE HEMANGIOMA; IRRITABILITY; MALE; MORPHOLOGICAL TRAIT; PAROTID GLAND; PRIORITY JOURNAL; PULSED DYE LASER; REBOUND; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SKIN DEFECT; SKIN EXAMINATION; SLEEP DISORDER; TREATMENT RESPONSE; TUMOR GROWTH; ULCER;

ADRENAL CORTEX HORMONES; AGE FACTORS; CHILD, PRESCHOOL; DISEASE PROGRESSION; HEMANGIOMA; HUMANS; INFANT; INTERFERON ALFA-2A; INTERFERON ALFA-2B; INTERFERONS; RETROSPECTIVE STUDIES; VINCRISTINE;

EID: 58049194002     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archderm.144.12.1632     Document Type: Article

References (18)

1. Drolet BA, Esterly NB, Frieden IJ. Hemangiomas in children. N Engl J Med. 1999;341(3):173-181.
2. Esterly NB. Cutaneous hemangiomas, vascular stains and malformations, and associated syndromes. Curr Probl Pediatr. 1996;26(1):3-39.
3. Bowers RE, Graham EA, Tomlinson KM. The natural history of the strawberry nevus. Arch Dermatol. 1960;82(4):667-679.
4. Chang LC, Haggstrom AN, Drolet BA, et al. The growth characteristics of infantile hemangiomas: implications for management. Pediatrics. 2008;122(2):360-367.
5. Nakayama H. Clinical and histological studies of the classification and the natural course of the strawberry mark. J Dermatol. 1981;8(4):277-291.
6. Haggstrom AN, Lammer EJ, Schneider RA, Marcucio R, Frieden IJ. Patterns of infantile hemangiomas: new clues to hemangioma pathogenesis and embryonic facial development. Pediatrics. 2006;117(3):698-703.
7. Waner M, North PE, Scherer KA, Frieden IJ, Waner A, Mihm MC Jr. The nonrandom distribution of facial hemangiomas. Arch Dermatol. 2003;139(7):869-875.
8. Chiller KG, Passaro D, Frieden IJ. Hemangiomas of infancy: clinical characteristics, morphologic subtypes, and their relationship to race, ethnicity, and sex. Arch Dermatol. 2002;138(12):1567-1576.
9. Haggstrom AN, Drolet BA, Baselga E, et al. Prospective study of infantile hemangiomas: clinical characteristics predicting complications and treatment. Pediatrics. 2006;118(3):882-887.
10. Metry DW, Hebert AA. Benign cutaneous vascular tumors of infancy: when to worry, what to do. Arch Dermatol. 2000;136(7):905-914.
11. Blei F, Isakoff M, Deb G. The response of parotid hemangiomas to the use of systemic interferon alfa-2a or corticosteroids. Arch Otolaryngol Head Neck Surg. 1997;123(8):841-844.
12. Greene AK, Rogers GF, Mulliken JB. Management of parotid hemangioma in 100 children. Plast Reconstr Surg. 2004;113(1):53-60.
13. Blei F, Rutkowski M. Transiently arterialized hemangiomas: relevant clinical and cardiac issues. Lymphat Res Biol. 2003;1(4):317-320.
14. Boon LM, MacDonald DM, Mulliken JB. Complications of systemic corticosteroid therapy for problematic hemangioma. Plast Reconstr Surg. 1999;104(6):1616-1623.
15. George ME, Sharma V, Jacobson J, Simon S, Nopper AJ. Adverse effects of systemic glucocorticosteroid therapy in infants with hemangiomas. Arch Dermatol. 2004;140(8):963-969.
16. Frieden IJ, Haggstrom AN, Drolet BA, et al. Infantile hemangiomas: current knowledge, future directions: proceedings of a research workshop on infantile hemangiomas, April 7-9, 2005, Bethesda, Maryland, USA. Pediatr Dermatol. 2005;22(5):383-406.
17. Sadan N, Wolach B. Treatment of hemangiomas of infants with high doses of prednisone. J Pediatr. 1996;128(1):141-146.
18. Ritter MR, Moreno SK, Dorrell MI, et al. Identifying potential regulators of infantile hemangioma progression through large-scale expression analysis: a possible role for the immune system and indoleamine 2,3 dioxygenase (IDO) during involution. Lymphat Res Biol. 2003;1(4):291-299.